A Study on the Safety and Efficacy of Tirzepatide in People with Type 2 Diabetes

A Study on the Safety and Efficacy of Tirzepatide in People with Type 2 Diabetes - A Study on the Safety and Efficacy of Tirzepatide in People with Type 2 Diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052214

Enrollment

Registered

2023-09-14

Start date

2023-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Tirzepatide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. People with Type 2 Diabetes 2. HbA1c levels between 6.5% and 10.0% in the last 4 to 8 weeks 3. People eligible for Tirzepatide use and scheduled for Tirzepatide administration.

Exclusion criteria

Exclusion criteria: 1. Individuals with severe anemia (Hb < 10g/dL) 2. Patinets with implanted medical devices (such as pacemakers) 3. Patients with active malignant tumors 4. Participants for whom the Principal Investigator or Sub-Investigator has determined are not suitable for participation in this clinical study.

Design outcomes

Primary

Measure	Time frame
The Percentage of Time within Target Glucose Range by Continuous Glucose Monitoring.	—

Countries

Japan

Contacts

Public ContactAkinori Hayashi

Kitasato University School of Medicine Endocrinology, Diabetes and Metabolism

ahayashi@kitasato-u.ac.jp0427788111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026